VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Yang, Jing ^a   Li, Wenlu ^b   He, Xin ^a   Zhang, Guofei ^a   Yue, Lan ^a   Chai, Ying ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; TUMOR MARKER; VASCULOTROPIN A;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CORRELATIONAL STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; GENE OVEREXPRESSION; HUMAN; META ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STUDY DESIGN; SURVIVAL RATE; SYSTEMATIC REVIEW; CASE CONTROL STUDY; GENETICS; LYMPHOMA, NON-HODGKIN; METABOLISM; UPREGULATION;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924565734     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/786790     Document Type: Review

References (46)

1. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013," CA: Cancer Journal for Clinicians, Vol. 63, no. 1, pp. 11-30, 2013.
2. "A predictive model for aggressive non-Hodgkin's lymphoma. The international Non-Hodgkin's Lymphoma Prognostic Factors Project," New England Journal of Medicine, Vol. 329, no. 14, pp. 987-994, 1993.
3. T. Sattar, L. K. Griffeth, H. R. Latifi, J. Glass, R. Munker, and D. L. Lilien, "PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin's lymphomas," The Journal of the Louisiana State Medical Society, Vol. 158, no. 4, pp. 193-201, 2006.
4. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, Vol. 144, no. 5, pp. 646-674, 2011.
5. J. M. Jørgensen, F. B. Sørensen, K. Bendix et al., "Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes," Leukemia & Lymphoma, Vol. 48, no. 3, pp. 584-595, 2007.
6. C.K. Poh, Z. Shi, T.Y. Lim, K.G. Neoh, and W. Wang, "The effect of VEGF functionalization of titanium on endothelial cells in vitro," Biomaterials, Vol. 31, no. 7, pp. 1578-1585, 2010.
7. Q. T. Ho and C. J. Kuo, "Vascular endothelial growth factor: biology and therapeutic applications," International Journal of Biochemistry and Cell Biology, Vol. 39, no. 7-8, pp. 1349-1357, 2007.
8. D. Ribatti, A. Vacca, B. Nico, M. Fanelli, L. Roncali, and F. Dammacco, "Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study," European Journal of Haematology, Vol. 56, no. 1-2, pp. 45-53, 1996.
9. A. Stang, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses," European Journal of Epidemiology, Vol. 25, no. 9, pp. 603-605, 2010.
10. M. K. B. Parmar, V. Torri, and L. Stewart, "Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints," Statistics in Medicine, Vol. 17, no. 24, pp. 2815-2834, 1998.
11. S. Yusuf, R. Peto, and J. Lewis, "Beta blockade during and after myocardial infarction: an overview of the randomized trials," Progress in Cardiovascular Diseases, Vol. 27, no. 5, pp. 335-371, 1985.
12. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses," British Medical Journal, Vol. 327, no. 7414, pp. 557-560, 2003.
13. N. Mantel and W. Haenszel, "Statistical aspects of the analysis of data from retrospective studies of disease," Journal of the National Cancer Institute, Vol. 22, no. 4, pp. 719-748, 1959.
14. P. Rujirojindakul and A. Lekhakula, "Prognostic significance of serum proangiogenic molecules in patients with de novo non-hodgkin lymphomas," The Scientific World Journal, Vol. 2012, Article ID 215231, 5 pages, 2012.
15. M. T. Bortolin, R. Tedeschi, E. Bidoli et al., "Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7," Cytokine, Vol. 60, no. 1, pp. 90-95, 2012.
16. S. Riihijärvi, H. Nurmi, H. Holte et al., "High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy," European Journal of Haematology, Vol. 89, no. 5, pp. 395-402, 2012.
17. S. I. Labidi, C. Ménétrier-Caux, S. Chabaud et al., "Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival," Annals of Hematology, Vol. 89, no. 1, pp. 25-33, 2010.
18. P. Bono, L. Teerenhovi, and H. Joensuu, "Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma," Cancer, Vol. 97, no. 11, pp. 2767-2775, 2003.
19. N. Niitsu, M. Okamoto, H. Nakamine et al., "Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma," European Journal of Haematology, Vol. 68, no. 2, pp. 91-100, 2002.
20. P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu, "Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients," Blood, Vol. 96, no. 12, pp. 3712-3718, 2000.
21. J. A. Kim, S. J. Kim, I.-G. Do et al., "Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?" Leukemia and Lymphoma, Vol. 52, no. 2, pp. 205-213, 2011.
22. W. Zhang, L. Wang, D. Zhou, Q. Cui, D. Zhao, and Y. Wu, "Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified," Leukemia and Lymphoma, Vol. 52, no. 1, pp. 46-52, 2011.
23. S. Paydas, G. Seydaoglu, M. Ergin, S. Erdogan, and S. Yavuz, "The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas," Leukemia and Lymphoma, Vol. 50, no. 3, pp. 366-373, 2009.
24. E. C. Citak, A. Oguz, C. Karadeniz, and N. Akyurek, "Role of gelatinases (MMP-2 and MMP-9), TIMP-1, vascular endothelial growth factor (VEGF), and microvessel density on the clinico-pathological behavior of childhood non-Hodgkin lymphoma," Pediatric Hematology and Oncology, Vol. 25, no. 1, pp. 55-66, 2008.
25. D. Gratzinger, S. Zhao, R. J. Tibshirani et al., "Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy," Laboratory Investigation, Vol. 88, no. 1, pp. 38-47, 2008.
26. I. Pazgal, O. Boycov, O. Shpilberg, E. Okon, and O. Bairey, "Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas," Leukemia and Lymphoma, Vol. 48, no. 11, pp. 2213-2220, 2007.
27. K. N. Ganjoo, A. M. Moore, A. Orazi, J. A. Sen, C. S. Johnson, and C. S. An, "The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients," Journal of Cancer Research and Clinical Oncology, Vol. 134, no. 3, pp. 381-387, 2008.
28. B. Hazar, S. Paydas, S. Zorludemir, B. Sahin, and I. Tuncer, "Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma," Leukemia and Lymphoma, Vol. 44, no. 12, pp. 2089-2093, 2003.
29. A. R. Perez-Atayde, S. E. Sallan, U. Tedrow, S. Connors, E. Allred, and J. Folkman, "Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia," The American Journal of Pathology, Vol. 150, no. 3, pp. 815-821, 1997.
30. G. Pruneri, F. Bertolini, D. Soligo et al., "Angiogenesis in myelodysplastic syndromes," British Journal of Cancer, Vol. 81, no. 8, pp. 1398-1401, 1999.
31. A. Vacca, D. Ribatti, M. Presta et al., "Bone marrow neo-vascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma," Blood, Vol. 93, no. 9, pp. 3064-3073, 1999.
32. P. Carmeliet, V. Ferreira, G. Breier et al., "Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele," Nature, Vol. 380, no. 6573, pp. 435-439, 1996.
33. M. D. Jacobson, J. F. Burne, M. P. King, T. Miyashita, J. C. Reed, and M. C. Raff, "Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA," Nature, Vol. 361, no. 6410, pp. 365-369, 1993.
34. A. Hajitou, C. Grignet, L. Devy et al., "The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells," The FASEB Journal, Vol. 16, no. 13, pp. 1802-1804, 2002.
35. D. Feliers, K. Woodruff, and S. Abboud, "Potential role of insulin-like growth factor binding protein-4 in the uncoupling of bone turnover in multiple myeloma," British Journal of Haematology, Vol. 104, no. 4, pp. 715-722, 1999.
36. D. Shweiki, A. Itin, D. Soffer, and E. Keshet, "Vascular endothe-lial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature, Vol. 359, no. 6398, pp. 843-845, 1992.
37. G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, "Vascular-specific growth factors and blood vessel formation," Nature, Vol. 407, no. 6801, pp. 242-248, 2000.
38. W. G. Jiang, T. A. Martin, C. Parr, G. Davies, K. Matsumoto, and T. Nakamura, "Hepatocyte growth factor, its receptor, and their potential value in cancer therapies," Critical Reviews in Oncology/Hematology, Vol. 53, no. 1, pp. 35-69, 2005.
39. H.-P. Gerber, A. K. Malik, G. P. Solar et al., "VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism," Nature, Vol. 417, no. 6892, pp. 954-958, 2002.
40. D. I. Gabrilovich, H. L. Chen, K. R. Girgis et al., "Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells," Nature Medicine, Vol. 2, no. 10, pp. 1096-1103, 1996.
41. B. Linderholm, K. Grankvist, N. Wilking, M. Johansson, B. Tavelin, and R. Henriksson, "Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment," Journal of Clinical Oncology, Vol. 18, no. 7, pp. 1423-1431, 2000.
42. A. Yuan, C.-J. Yu, W.-J. Chen et al., "Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer," International Journal of Cancer, Vol. 89, no. 6, pp. 475-483, 2000.
43. P. Salven, L. Teerenhovi, and H. Joensuu, "A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma," Blood, Vol. 90, no. 8, pp. 3167-3172, 1997.
44. N. Ferrara, K. J. Hillan, H.-P. Gerber, and W. Novotny, "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer," Nature Reviews Drug Discovery, Vol. 3, no. 5, pp. 391-400, 2004.
45. A. T. Stopeck, J. M. Unger, L. M. Rimsza et al., "A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkinlymphoma: Southwest oncologygroup study S0108," Leukemia and Lymphoma, Vol. 50, no. 5, pp. 728-735, 2009.
46. K. N. Ganjoo, C. S. An, M. J. Robertson et al., "Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis," Leukemia and Lymphoma, Vol. 47, no. 6, pp. 998-1005, 2006.